Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.

Mitcheson, Henry D; Samanta, Suvajit; Muldowney, Karen; Pinto, Cathy A; Rocha, Beatriz de A; Green, Stuart; Bennett, Nathan; Mudd, Paul N; Frenkl, Tara L

Mitcheson, Henry D; Samanta, Suvajit; Muldowney, Karen; Pinto, Cathy A; Rocha, Beatriz de A; Green, Stuart; Bennett, Nathan; Mudd, Paul N; Frenkl, Tara L.

Affiliation

Mitcheson HD; Bay State Urologists Inc, Bay State Clinical Trials Inc, Tufts University School of Medicine, Boston, MA, USA.
Samanta S; Merck & Co., Inc., Kenilworth, NJ, USA.
Muldowney K; Merck & Co., Inc., Kenilworth, NJ, USA.
Pinto CA; Merck & Co., Inc., Kenilworth, NJ, USA.
Rocha BA; Merck & Co., Inc., Kenilworth, NJ, USA.
Green S; Merck & Co., Inc., Kenilworth, NJ, USA.
Bennett N; Urovant Sciences, Inc., Irvine, CA, USA.
Mudd PN; Urovant Sciences, Inc., Irvine, CA, USA.
Frenkl TL; Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: tara_frenkl@merck.com.

Eur Urol ; 75(2): 274-282, 2019 02.

Article in En | MEDLINE | ID: mdl-30661513

Subject(s)
Key words

Dry mouth; Micturitions; Overactive bladder; Tolterodine; Urge incontinence; Urinary frequency; Urinary urgency; Vibegron; ß3-Adrenergic receptor agonist

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidinones / Pyrrolidines / Urinary Bladder / Muscarinic Antagonists / Urinary Bladder, Overactive / Adrenergic beta-3 Receptor Agonists / Tolterodine Tartrate Type of study: Clinical_trials / Diagnostic_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur Urol Year: 2019 Document type: Article Affiliation country: Estados Unidos Country of publication: Suiza

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google